GBM models show that oxamate, an LDH inhibitor, reduces H3K18 lactylation to downregulate CD73 and CCR8 expression, enhancing CAR-T cell efficacy against GBM by altering the phenotype of immune molecules in the TME and increasing the infiltration of CAR-T regulatory T cells in GBM [124]. The gene discussed is NT5E; the disease is glioblastoma.